

**DEPARTMENT OF HEALTH CARE FINANCE
NOTICE OF PUBLIC MEETING**

Department of Health Care Finance Pharmacy and Therapeutics Committee

The Department of Health Care Finance (DHCF) Pharmacy and Therapeutics Committee (Committee), pursuant to the requirements of Mayor's Order 2007-46, dated January 23, 2007, hereby announces a public meeting of the Committee to obtain input on the review and maintenance of a Preferred Drug List (PDL) for the District of Columbia. The meeting will be held **Thursday, September 8, 2011**, at 1:30pm in the 6th Floor Conference Room 1 at 899 North Capitol Street, NE Washington, DC 20002.

The Committee will receive public comments from interested individuals on issues relating to the topics or class reviews to be discussed at this meeting. The clinical drug class review for this meeting will include:

September Categories

Antivirals, Herpes	Fibromyalgia Agents
Antivirals, Influenza Agents	Multiple Sclerosis Agents
Fluoroquinolones, Oral	Sedative Hypnotics
Hepatitis B, Oral Agents	Stimulants & Related Agents
Hepatitis C Agents	Antibiotics, GI
Alzheimer's Agents	Antiemetics - Oral
Anticonvulsants	H. Pylori Combinations
Antidepressants, SSRIs	Histamine-2-Receptor Antagonists
Antidepressants, other	Ulcerative Colitis Agents (Oral and
Antiparkinson's Agents- Dopamine Agonists	Cytokine, CAM Antagonists & Related
Antipsychotics - Atypical	Immunosuppressants

Any person or organizations who wish to make a presentation to the DHCF P&T Committee should furnish his or her name, address, telephone number, and name of organization represented by calling (202) 442-9076 **no later than 4:45pm on Wednesday, August 31, 2011**. The person or organization may also submit the aforementioned information via e-mail to Charlene Fairfax (charlene.fairfax@dc.gov).

An individual wishing to make an oral presentation to the Committee will be limited to three (3) minutes. A person wishing to provide written information should supply twenty (20) copies of the written information to the Committee **no later than 4:45pm on Wednesday, August 31, 2011**. **Handouts are limited to no more than two standard 8-1/2 by 11 inch pages of "bulleted" points (or one page front and back)**. The ready-to-disseminate, written information can also be mailed to arrive **no later than August 31, 2011** to:

Department of Health Care Finance
Attention: Charlene Fairfax, RPh, CDE
899 North Capitol Street, NE, 6th floor
Washington, DC 20002

Due to cancellation of the June meeting as a result of the grid power outage, the following **June** categories will also be considered.

Self-Injectable Epinephrine	Carbonic Anhydrase Inhibitors- Glaucoma
Beta Adrenergic/Corticosteroid Combinations	Ophthalmic Antihistamines
COPD Anticholinergics	Ophthalmic Macrolides
Inhaled Corticosteroids	Ophthalmic Mast Cell Stabilizers
Intranasal Antihistamines	Ophthalmic NSAIDs
Leukotriene Modifiers & Formation Inhibitors	Ophthalmic Prostaglandin Agonists
Long Acting Beta Adrenergic Agents & Nebs	Ophthalmic Quinolones
Low-Sedating Antihistamines & Combinations	Otic Quinolones
Short Acting Beta Adrenergic Agents & Nebs	Serotonin Receptor Agonists
Nasal Steroids	Topical NSAIDs
Endothelin Receptor Antagonists (Oral Agents)	Skeletal Muscle Relaxants
Alpha-2-Adrenergic Agents - Glaucoma	Narcotics – Long Acting
Beta Blockers - Glaucoma	

No new speakers will be permitted for the June categories. No new information will be allowed for the June categories. If you previously registered to speak or sent information for the June categories, please send a confirmation e-mail to Charlene Fairfax to confirm your continued intent to speak. That meeting notice was originally posted on 4/22/2011.